Cat. No.: HY-10572

Efavirenz

(Synonyms: DMP 266; EFV; L-743726)

17 Cited Publications

Avis client

Based on 17 publication(s) in Google Scholar

Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a K_i of 2.93 nM and exhibits an IC₉₅ of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.93%
CAS No.: 154598-52-4
Formule: C₁₄H₉ClF₃NO₂
Masse moléculaire:315.68

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Efavirenz Chemical Structure

CAS No.: 154598-52-4

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (17)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

HIV-1

Voir tous les produits spécifiques à Isoform HIV :

Voir tous les produits spécifiques à Isoform Endogenous Metabolite :

Voir tous les produits spécifiques à Isoform Parasite :

Cellular Effect

Cell Line	Type	Value	Description	References
C8166	EC₅₀	0.0027 μM Compound: efavirenz	Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay	[PMID: 19170521]
C8166	EC₅₀	183.63 μM Compound: EFV	Antiviral activity against HIV1 A17 infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method Antiviral activity against HIV1 A17 infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method	[PMID: 27039251]
CCRF-CEM	CC₅₀	>200 μM Compound: Efavirenz	Concentration required to reduce the viability of mock-infected human CEM cells Concentration required to reduce the viability of mock-infected human CEM cells	[PMID: 16115762]
CCRF-CEM	EC₅₀	0.78 μM Compound: Efavirenz	Effective concentration required to inhibit HTLV-III B induced cytopathicity in human CEM cells Effective concentration required to inhibit HTLV-III B induced cytopathicity in human CEM cells	[PMID: 16115762]
CCRF-CEM	EC₅₀	0.0027 μM Compound: efavirenz	Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of virus-induced giant cell formation Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of virus-induced giant cell formation	[PMID: 17276064]
CCRF-CEM	EC₅₀	0.0061 μM Compound: efavirenz	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in CEM cells assessed as inhibition of virus-induced giant cell formation Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	[PMID: 17276064]
CCRF-CEM	EC₅₀	0.0096 μM Compound: efavirenz	Antiviral activity against HIV1 with reverse transcriptase E138K mutation in CEM cells assessed as inhibition of virus-induced giant cell formation Antiviral activity against HIV1 with reverse transcriptase E138K mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	[PMID: 17276064]
CCRF-CEM	EC₅₀	0.049 μM Compound: efavirenz	Antiviral activity against HIV1 with reverse transcriptase Y188H mutation in CEM cells assessed as inhibition of virus-induced giant cell formation Antiviral activity against HIV1 with reverse transcriptase Y188H mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	[PMID: 17276064]
CCRF-CEM	EC₅₀	0.0573 μM Compound: efavirenz	Antiviral activity against HIV1 with reverse transcriptase L100I mutation in CEM cells assessed as inhibition of virus-induced giant cell formation Antiviral activity against HIV1 with reverse transcriptase L100I mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	[PMID: 17276064]
CCRF-CEM	EC₅₀	0.218 μM Compound: efavirenz	Antiviral activity against HIV1 with reverse transcriptase K103N mutation in CEM cells assessed as inhibition of virus-induced giant cell formation Antiviral activity against HIV1 with reverse transcriptase K103N mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	[PMID: 17276064]
CCRF-CEM	IC₅₀	12 nM Compound: EFV	Antiviral activity against HIV1 with reverse transcriptase Y181I mutation in human CEM cells assessed as protection against virus-induced cytopathicity Antiviral activity against HIV1 with reverse transcriptase Y181I mutation in human CEM cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
CCRF-CEM	IC₅₀	130 nM Compound: EFV	Antiviral activity against HIV1 with reverse transcriptase K103N mutation in human CEM cells assessed as protection against virus-induced cytopathicity Antiviral activity against HIV1 with reverse transcriptase K103N mutation in human CEM cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
CCRF-CEM	IC₅₀	160 nM Compound: EFV	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human CEM cells assessed as protection against virus-induced cytopathicity Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human CEM cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
CCRF-CEM	IC₅₀	22 nM Compound: EFV	Antiviral activity against HIV1 with reverse transcriptase L100I mutation in human CEM cells assessed as protection against virus-induced cytopathicity Antiviral activity against HIV1 with reverse transcriptase L100I mutation in human CEM cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
CCRF-CEM	IC₅₀	760 nM Compound: EFV	Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in human CEM cells assessed as protection against virus-induced cytopathicity Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in human CEM cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
CCRF-CEM	CC₅₀	>10000 μM Compound: EFV	Cytotoxicity against human CEM cells by coulter counter analysis Cytotoxicity against human CEM cells by coulter counter analysis	[PMID: 21366296]
CCRF-CEM	EC₅₀	>10000 nM Compound: EFV	Antiviral activity against HIV2 isolate ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis Antiviral activity against HIV2 isolate ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis	[PMID: 21366296]
CCRF-CEM	EC₅₀	1.5 nM Compound: EFV	Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis	[PMID: 21366296]
CCRF-CEM	EC₅₀	>10000 nM Compound: EFV, DMP-266	Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy	[PMID: 24769348]
CCRF-CEM	EC₅₀	1.5 nM Compound: EFV, DMP-266	Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy	[PMID: 24769348]
CCRF-CEM	EC₅₀	>10000 nM Compound: EFV, DMP-266	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay Antiviral activity against HIV2 ROD infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay	[PMID: 25418038]
CCRF-CEM	EC₅₀	1.5 nM Compound: EFV, DMP-266	Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay	[PMID: 25418038]
CCRF-CEM	CC₅₀	>100 μM Compound: EFV	Cytotoxicity against HIV1 infected human CEM cells assessed as reduction in cell viability after 7 days by MTT assay Cytotoxicity against HIV1 infected human CEM cells assessed as reduction in cell viability after 7 days by MTT assay	[PMID: 27390064]
CEM-SS	EC₅₀	0.005 μM Compound: efavirenz	Antiviral activity against HIV1 RF in human CEM-SS cells by XTT assay Antiviral activity against HIV1 RF in human CEM-SS cells by XTT assay	[PMID: 17803290]
CEM-SS	EC₅₀	>1 μM Compound: EFZ	Antiviral activity against HIV1 NL4-3 containing reverse transcriptase K103N mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HIV1 NL4-3 containing reverse transcriptase K103N mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 20888224]
CEM-SS	EC₅₀	0.004 μM Compound: EFZ	Antiviral activity against wild type HIV1 NL4-3 infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against wild type HIV1 NL4-3 infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 20888224]
CEM-SS	EC₅₀	0.005 μM Compound: EFZ	Antiviral activity against HIV1 NL4-3 containing reverse transcriptase Y181C mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HIV1 NL4-3 containing reverse transcriptase Y181C mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 20888224]
CEM-SS	CC₅₀	0.55 μM Compound: Efavirenz	Cytotoxicity against human CEM-SS cells by MTS assay Cytotoxicity against human CEM-SS cells by MTS assay	10.1039/C4MD00282B
CEM-SS	EC₅₀	0.92 nM Compound: Efavirenz	Antiviral activity against HIV1 RF infected in CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by MTS assay Antiviral activity against HIV1 RF infected in CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by MTS assay	10.1039/C4MD00282B
HEK293	CC₅₀	10 μM Compound: efavirenz	Cytotoxicity against HEK293T cells Cytotoxicity against HEK293T cells	[PMID: 16464578]
HEK293	CC₅₀	10 μM Compound: efavirenz	Cytotoxicity against HEK293T cells Cytotoxicity against HEK293T cells	[PMID: 16480865]
HEK293	CC₅₀	10 μM Compound: 1, Efavirenz	Cytotoxicity against HEK293T cells Cytotoxicity against HEK293T cells	[PMID: 16782337]
HEK293	IC₅₀	40.6 μM Compound: Efavirenz	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability Cytotoxicity against human HEK293 cells assessed as reduction in cell viability	[PMID: 32937282]
HEK-293T	EC₅₀	0.0005 μM Compound: efavirenz	Antiviral activity against HIV1 in HEK293T cells Antiviral activity against HIV1 in HEK293T cells	[PMID: 16464578]
HEK-293T	EC₅₀	0.0005 μM Compound: efavirenz	Antiviral activity against HIV1 in HEK293T cells Antiviral activity against HIV1 in HEK293T cells	[PMID: 16480865]
HEK-293T	CC₅₀	10 μM Compound: efavirenz	Cytotoxicity against HEK293T cells after 48 hrs Cytotoxicity against HEK293T cells after 48 hrs	[PMID: 17035019]
HEK-293T	EC₅₀	0.0005 μM Compound: efavirenz	Antiviral activity against HIV in HEK293T cells after 48 hrs Antiviral activity against HIV in HEK293T cells after 48 hrs	[PMID: 17035019]
HEK-293T	EC₅₀	889 nM Compound: EFV	Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay	[PMID: 22148316]
HEK-293T	IC₅₀	0.00084 μM Compound: EFV	Antiviral activity against wild type HIV1 infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against wild type HIV1 infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	0.00565 μM Compound: EFV	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	0.056 μM Compound: EFV	Antiviral activity against HIV1 harboring reverse transcriptase K103N/G190A double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/G190A double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	0.0588 μM Compound: EFV	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	0.083 μM Compound: EFV	Antiviral activity against HIV1 harboring reverse transcriptase K103N/V108I double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/V108I double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	0.16 μM Compound: EFV	Antiviral activity against HIV1 harboring reverse transcriptase K103N/P225H double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/P225H double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	0.48 μM Compound: EFV	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	2.49 μM Compound: EFV	Antiviral activity against HIV1 harboring reverse transcriptase L1001/K103N double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase L1001/K103N double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	0.00104 μM Compound: EFV	Antiviral activity against wild-type HIV-1 NL4-3 harboring vesicular stomatitis virus glycoprotein infected in HEK293T cells pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene assay Antiviral activity against wild-type HIV-1 NL4-3 harboring vesicular stomatitis virus glycoprotein infected in HEK293T cells pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene assay	[PMID: 27484516]
HEK-293T	IC₅₀	0.00565 μM Compound: EFV	Antiviral activity against HIV-1 NL4-3 harboring RT-Y181C mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene Antiviral activity against HIV-1 NL4-3 harboring RT-Y181C mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene	[PMID: 27484516]
HEK-293T	IC₅₀	0.056 μM Compound: EFV	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/G190A double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/G190A double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	[PMID: 27484516]
HEK-293T	IC₅₀	0.0587 μM Compound: EFV	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y181C double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y181C double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	[PMID: 27484516]
HEK-293T	IC₅₀	0.0588 μM Compound: EFV	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene Antiviral activity against HIV-1 NL4-3 harboring RT-K103N mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene	[PMID: 27484516]
HEK-293T	IC₅₀	0.083 μM Compound: EFV	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/V108I double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/V108I double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	[PMID: 27484516]
HEK-293T	IC₅₀	0.16 μM Compound: EFV	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/P225H double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/P225H double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	[PMID: 27484516]
HEK-293T	IC₅₀	0.48 μM Compound: EFV	Antiviral activity against HIV-1 NL4-3 harboring RT-Y188L mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene Antiviral activity against HIV-1 NL4-3 harboring RT-Y188L mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene	[PMID: 27484516]
HEK-293T	IC₅₀	13.8 μM Compound: EFV	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y188L double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y188L double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	[PMID: 27484516]
HEK-293T	IC₅₀	2.49 μM Compound: EFV	Antiviral activity against HIV-1 NL4-3 harboring RT-L100I/K103N double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase Antiviral activity against HIV-1 NL4-3 harboring RT-L100I/K103N double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	[PMID: 27484516]
HEK-293T	CC₅₀	>30 μM Compound: Efavirenz	Cytotoxicity against human HEK 293T cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-glo assay Cytotoxicity against human HEK 293T cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-glo assay	[PMID: 32004936]
HeLa	IC₅₀	0.0005 μM Compound: EFV	Antiviral activity against P236L mutant virus in the HeLa MAGI assay. Antiviral activity against P236L mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	0.0008 μM Compound: EFV	Antiviral activity against E138K mutant virus in the HeLa MAGI assay. Antiviral activity against E138K mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	0.0009 μM Compound: EFV	Antiviral activity against wild-type HIV-1 in the HeLa MAGI assay. Antiviral activity against wild-type HIV-1 in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	0.0012 μM Compound: EFV	Antiviral activity against Y188C mutant virus in the HeLa MAGI assay. Antiviral activity against Y188C mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	0.0014 μM Compound: EFV	Antiviral activity against V108I mutant virus in the HeLa MAGI assay. Antiviral activity against V108I mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	0.0015 μM Compound: EFV	Antiviral activity against V106A mutant virus in the HeLa MAGI assay. Antiviral activity against V106A mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	0.0018 μM Compound: EFV	Antiviral activity against Y181C mutant virus in the HeLa MAGI assay. Antiviral activity against Y181C mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	0.0033 μM Compound: EFV	Antiviral activity against V106A/Y181C mutant virus in the HeLa MAGI assay. Antiviral activity against V106A/Y181C mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	0.0033 μM Compound: EFV	Antiviral activity against V108I/Y181C mutant virus in the HeLa MAGI assay. Antiviral activity against V108I/Y181C mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	0.0064 μM Compound: EFV	Antiviral activity against G190A mutant virus in the HeLa MAGI assay. Antiviral activity against G190A mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	0.024 μM Compound: EFV	Antiviral activity against K103N mutant virus in the HeLa MAGI assay. Antiviral activity against K103N mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	0.042 μM Compound: EFV	Antiviral activity against K103N/Y181C mutant virus in the HeLa MAGI assay. Antiviral activity against K103N/Y181C mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	0.074 μM Compound: EFV	Antiviral activity against K103N/V108I mutant virus in the HeLa MAGI assay. Antiviral activity against K103N/V108I mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	0.13 μM Compound: EFV	Antiviral activity against K103N/P225H mutant virus in the HeLa MAGI assay. Antiviral activity against K103N/P225H mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	1.6 μM Compound: EFV	Antiviral activity against K103N/L100I mutant virus in the HeLa MAGI assay. Antiviral activity against K103N/L100I mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	1 nM Compound: Efavirenz	Inhibitory concentration against human immunodeficiency virus type 1 (with V106A resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with V106A resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	1 nM Compound: Efavirenz	Inhibitory concentration against human immunodeficiency virus type 1 (with Y188C resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with Y188C resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	1.4 nM Compound: Efavirenz	Inhibitory concentration against human immunodeficiency virus type 1 (with V108I resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with V108I resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	2 nM Compound: Efavirenz	Inhibitory concentration against human immunodeficiency virus type 1 (with Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	23 nM Compound: Efavirenz	Inhibitory concentration against human immunodeficiency virus type 1 (with K103N resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with K103N resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	3 nM Compound: Efavirenz	Inhibitory concentration against human immunodeficiency virus type 1 (with V106A/Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with V106A/Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	3 nM Compound: Efavirenz	Inhibitory concentration against human immunodeficiency virus type 1 (with V108I/Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with V108I/Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	43 nM Compound: Efavirenz	Inhibitory concentration against human immunodeficiency virus type 1 (with K103N/Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with K103N/Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	552 nM Compound: Efavirenz	Inhibitory concentration against human immunodeficiency virus type 1 (with K103N/G190A resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with K103N/G190A resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	7 nM Compound: Efavirenz	Inhibitory concentration against human immunodeficiency virus type 1 (with G190A resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with G190A resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	74 nM Compound: Efavirenz	Inhibitory concentration against human immunodeficiency virus type 1 (with K103N/V108I resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with K103N/V108I resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	EC₅₀	0.0004 μM Compound: EFV	Antiviral activity against wild type HIV1 in HeLa-JC53 cells Antiviral activity against wild type HIV1 in HeLa-JC53 cells	[PMID: 16806925]
HeLa	EC₅₀	0.011 μM Compound: EFV	Antiviral activity against HIV1 K103N-Y181C mutant in HeLa-JC53 cells Antiviral activity against HIV1 K103N-Y181C mutant in HeLa-JC53 cells	[PMID: 16806925]
HeLa	EC₅₀	0.073 μM Compound: EFV	Antiviral activity against HIV1 Y188L mutant in HeLa-JC53 cells Antiviral activity against HIV1 Y188L mutant in HeLa-JC53 cells	[PMID: 16806925]
HeLa	EC₅₀	>0.002 μM Compound: EFV	Antiviral activity against HIV1 bearing HIV1 NL4-3 envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay Antiviral activity against HIV1 bearing HIV1 NL4-3 envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay	[PMID: 17646410]
HeLa	EC₅₀	0.0011 μM Compound: EFV	Antiviral activity against HIV1 bearing VSV envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay Antiviral activity against HIV1 bearing VSV envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay	[PMID: 17646410]
HeLa	EC₅₀	0.0001 μM Compound: Efavirenz	Antiviral activity against HIV1 infected in human HeLa cells expressing CD4-LTR assessed as inhibition of viral entry-related beta galactosidase expression treated for 2 hrs measured after 48 hrs by MAGI assay Antiviral activity against HIV1 infected in human HeLa cells expressing CD4-LTR assessed as inhibition of viral entry-related beta galactosidase expression treated for 2 hrs measured after 48 hrs by MAGI assay	[PMID: 17967909]
HeLa	IC₅₀	0.4 nM Compound: efavirenz, EFV	Antiviral activity against wild type HIV1 in HeLa cells by MAGI assay Antiviral activity against wild type HIV1 in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	0.6 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P236L mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P236L mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	0.8 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	0.8 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y181C mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y181C mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	0.9 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	1 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190E mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190E mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	1.2 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase E138K mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase E138K mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	1.2 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188C mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188C mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	1.3 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P225H mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P225H mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	1.8 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	1198 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/L100I mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/L100I mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	140 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/P225H mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/P225H mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	154 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188L mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188L mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	17 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	2 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A/Y181C mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A/Y181C mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	2.3 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K101E mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K101E mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	2.7 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I/Y181C mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I/Y181C mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	21 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase L100I mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase L100I mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	3 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I/Y181C mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I/Y181C mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	44 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/Y181C mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/Y181C mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	485 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/G190A mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/G190A mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	5.9 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190A mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190A mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	7.2 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106M mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106M mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	89 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190S mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190S mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	94 nM Compound: efavirenz, EFV	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/V108I mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/V108I mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	EC₅₀	0.0006 μM Compound: EFV	Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
HeLa	EC₅₀	0.0006 μM Compound: EFV	Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
HeLa	EC₅₀	0.001 μM Compound: EFV	Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
HeLa	EC₅₀	0.001 μM Compound: EFV	Antiviral activity against HIV1 NL4-3 infected in human HeLa cells assessed as decrease in single-cycle viral infection after 72 hrs by beta-galactosidase reporter gene assay Antiviral activity against HIV1 NL4-3 infected in human HeLa cells assessed as decrease in single-cycle viral infection after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 19805571]
MRC5	IC₅₀	25.84 μM Compound: Efavirenz	Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs	[PMID: 25199582]
MRC5	IC₅₀	8.56 μM Compound: Efavirenz	Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay	[PMID: 25199582]
MT2	CC₅₀	>0.1 μM Compound: efavirenz	Cytotoxicity against MT2 cells Cytotoxicity against MT2 cells	[PMID: 16931015]
MT2	EC₅₀	0.002 μM Compound: efavirenz	Antiviral activity against HIV1 3B in MT2 cells Antiviral activity against HIV1 3B in MT2 cells	[PMID: 16931015]
MT2	CC₅₀	3 μM Compound: 5	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 17918923]
MT2	EC₅₀	0.0001 μM Compound: EFV	Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.0002 μM Compound: EFV	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.0002 μM Compound: EFV	Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.0002 μM Compound: EFV	Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT infected in human MT2 cells Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT infected in human MT2 cells	[PMID: 18316521]
MT2	EC₅₀	0.0002 μM Compound: EFV	Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells	[PMID: 18316521]
MT2	EC₅₀	0.0003 μM Compound: EFV	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.0003 μM Compound: EFV	Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.0003 μM Compound: EFV	Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.0003 μM Compound: EFV	Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.00034 μM Compound: EFV	Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay	[PMID: 18316521]
MT2	EC₅₀	0.0004 μM Compound: EFV	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.0004 μM Compound: EFV	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.0004 μM Compound: EFV	Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.0007 μM Compound: EFV	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.0007 μM Compound: EFV	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.0008 μM Compound: EFV	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.0009 μM Compound: EFV	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.0009 μM Compound: EFV	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.001 μM Compound: EFV	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.0011 μM Compound: EFV	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.0012 μM Compound: EFV	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.0012 μM Compound: EFV	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	0.0013 μM Compound: EFV	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.0017 μM Compound: EFV	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	[PMID: 18316521]
MT2	EC₅₀	0.003 μM Compound: EFV	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	[PMID: 18316521]
MT2	EC₅₀	6.8 nM Compound: EFV	Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS	[PMID: 19104010]
MT2	EC₅₀	1.1 nM Compound: Efavirenz	Antiviral activity against wild type HIV1 infected in human MT2 cells Antiviral activity against wild type HIV1 infected in human MT2 cells	[PMID: 20137928]
MT2	EC₅₀	2.6 nM Compound: Efavirenz	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells	[PMID: 20137928]
MT2	EC₅₀	35 nM Compound: Efavirenz	Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT2 cells Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT2 cells	[PMID: 20137928]
MT2	EC₅₀	1.1 nM Compound: Efavirenz	Antiviral activity against wild type HIV1 infected in human MT2 cells Antiviral activity against wild type HIV1 infected in human MT2 cells	[PMID: 20138513]
MT2	EC₅₀	2.6 nM Compound: Efavirenz	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells	[PMID: 20138513]
MT2	EC₅₀	35 nM Compound: Efavirenz	Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT2 cells Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT2 cells	[PMID: 20138513]
MT2	CC₅₀	>0.1 μM Compound: Evafirenz	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 20304641]
MT2	CC₅₀	>0.1 μM Compound: Evafirenz	Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay	[PMID: 20304641]
MT2	CC₅₀	>0.1 μM Compound: Evafirenz	Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay	[PMID: 20304641]
MT2	EC₅₀	0.002 μM Compound: Evafirenz	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay	[PMID: 20304641]
MT2	EC₅₀	0.01 μM Compound: Evafirenz	Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay	[PMID: 20304641]
MT2	EC₅₀	0.03 μM Compound: Evafirenz	Antiviral activity against HIV1 reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay Antiviral activity against HIV1 reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay	[PMID: 20304641]
MT2	EC₅₀	0.005 nM Compound: EFV, DMP-266, L-743, L-726	Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.005 multiplicities of infection after 6 days Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.005 multiplicities of infection after 6 days	[PMID: 20660667]
MT2	EC₅₀	0.05 nM Compound: EFV, DMP-266, L-743, L-726	Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.05 multiplicities of infection after 6 days Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.05 multiplicities of infection after 6 days	[PMID: 20660667]
MT2	EC₅₀	0.5 nM Compound: EFV, DMP-266, L-743, L-726	Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.5 multiplicities of infection after 6 days Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.5 multiplicities of infection after 6 days	[PMID: 20660667]
MT2	EC₅₀	1.2 nM Compound: EFV	Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay	[PMID: 21745701]
MT2	CC₅₀	15 μM Compound: Efavirenz	Cytotoxicity against human MT2 cells infected with HIV1 NL4.3 by MTT assay Cytotoxicity against human MT2 cells infected with HIV1 NL4.3 by MTT assay	[PMID: 22081993]
MT2	EC₅₀	0.002 μM Compound: Efavirenz	Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT2 cells assessed as inhibition of viral infection Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT2 cells assessed as inhibition of viral infection	[PMID: 22081993]
MT2	EC₅₀	0.01 μM Compound: Efavirenz	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral infection Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral infection	[PMID: 22081993]
MT2	EC₅₀	0.03 μM Compound: Efavirenz	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase K103N and Y181C double mutant infected in human MT2 cells assessed as inhibition of viral infection Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase K103N and Y181C double mutant infected in human MT2 cells assessed as inhibition of viral infection	[PMID: 22081993]
MT2	CC₅₀	15 μM Compound: Efavirenz	Cytotoxicity in human MT2 cells assessed as inhibition of cell growth Cytotoxicity in human MT2 cells assessed as inhibition of cell growth	[PMID: 23298809]
MT2	EC₅₀	0.002 μM Compound: Efavirenz	Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method	[PMID: 23298809]
MT2	EC₅₀	0.01 μM Compound: Efavirenz	Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method	[PMID: 23298809]
MT2	EC₅₀	0.03 μM Compound: Efavirenz	Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase K103N and Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase K103N and Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method	[PMID: 23298809]
MT2	CC₅₀	15 μM Compound: Efavirenz	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 23899617]
MT2	EC₅₀	0.002 μM Compound: Efavirenz	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay	[PMID: 23899617]
MT2	CC₅₀	15 μM Compound: Efavirenz	Cytotoxicity against human MT2 cells assessed as growth inhibition Cytotoxicity against human MT2 cells assessed as growth inhibition	[PMID: 23937980]
MT2	EC₅₀	0.002 μM Compound: Efavirenz	Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay	[PMID: 23937980]
MT2	EC₅₀	0.01 μM Compound: Efavirenz	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay	[PMID: 23937980]
MT2	EC₅₀	0.03 μM Compound: Efavirenz	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay	[PMID: 23937980]
MT2	CC₅₀	15 μM Compound: efv	Cytotoxicity against human MT2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT2 cells assessed as reduction in cell viability by MTT assay	[PMID: 25408842]
MT2	EC₅₀	0.002 μM Compound: efv	Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay	[PMID: 25408842]
MT2	EC₅₀	0.01 μM Compound: efv	Antiviral activity against wild type HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay Antiviral activity against wild type HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay	[PMID: 25408842]
MT2	EC₅₀	0.03 μM Compound: efv	Antiviral activity against wild type HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay Antiviral activity against wild type HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay	[PMID: 25408842]
MT2	CC₅₀	15 μM Compound: Efavirenz	Cytotoxicity against human MT2 cells assessed as growth inhibition by MTT method Cytotoxicity against human MT2 cells assessed as growth inhibition by MTT method	[PMID: 27485603]
MT2	EC₅₀	15 μM Compound: Efavirenz	Cytotoxicity against human MT2 cells assessed as cell viability by MTT assay Cytotoxicity against human MT2 cells assessed as cell viability by MTT assay	[PMID: 35175760]
MT4	ED₅₀	0.005 μM Compound: DMP 266	Inhibition of wild type HIV-1 in MT-4 cell culture (human T cell line) Inhibition of wild type HIV-1 in MT-4 cell culture (human T cell line)	[PMID: 10514285]
MT4	ED₅₀	0.016 μM Compound: DMP 266	Inhibitory activity against HIV-1 Cys 181 mutant in MT-4 cells. Inhibitory activity against HIV-1 Cys 181 mutant in MT-4 cells.	[PMID: 10514285]
MT4	ED₅₀	0.05 μM Compound: DMP 266	Inhibitory activity against HIV-1 Wild Type in MT-4 cell culture (human T-cell line with 50% human AB serum) Inhibitory activity against HIV-1 Wild Type in MT-4 cell culture (human T-cell line with 50% human AB serum)	[PMID: 10514285]
MT4	ED₅₀	0.06 μM Compound: DMP 266	Inhibitory activity against HIV-1 Ile 100 mutant in MT-4 cells. Inhibitory activity against HIV-1 Ile 100 mutant in MT-4 cells.	[PMID: 10514285]
MT4	ED₅₀	0.14 μM Compound: DMP 266	Inhibitory activity against HIV-1 Asn 103 mutant in MT-4 cells. Inhibitory activity against HIV-1 Asn 103 mutant in MT-4 cells.	[PMID: 10514285]
MT4	EC₅₀	0.004 μM Compound: Efavirenz	Anti-HIV-1 activity against WTIIIB HIV-1 strain in MT-4 cells Anti-HIV-1 activity against WTIIIB HIV-1 strain in MT-4 cells	[PMID: 11472208]
MT4	EC₅₀	0.025 μM Compound: Efavirenz	Anti-HIV-1 activity against Y181C HIV-1 strain in MT-4 cells Anti-HIV-1 activity against Y181C HIV-1 strain in MT-4 cells	[PMID: 11472208]
MT4	IC₅₀	>10 μM Compound: Efavirenz	Inhibitory activity against 100I strain and 103N strain of HIV-I in MT-4 cells Inhibitory activity against 100I strain and 103N strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	0.001 μM Compound: Efavirenz	Inhibitory activity against LAI strain of HIV-I in MT-4 cells Inhibitory activity against LAI strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	0.002 μM Compound: Efavirenz	Inhibitory activity against 181C strain of HIV-I in MT-4 cells Inhibitory activity against 181C strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	0.04 μM Compound: Efavirenz	Inhibitory activity against 100I strain of HIV-I in MT-4 cells Inhibitory activity against 100I strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	0.04 μM Compound: Efavirenz	Inhibitory activity against 103N strain and 181C strain of HIV-I in MT-4 cells Inhibitory activity against 103N strain and 181C strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	0.04 μM Compound: Efavirenz	Inhibitory activity against 103N strain of HIV-I in MT-4 cells Inhibitory activity against 103N strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	0.158 μM Compound: Efavirenz	Inhibitory activity against 188L strain of HIV-I in MT-4 cells Inhibitory activity against 188L strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	>10 μM Compound: Efavirenz	Anti-HIV-1 activity against K103N+K1001 strain was determined in MT-4 cells by the MTT method Anti-HIV-1 activity against K103N+K1001 strain was determined in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	IC₅₀	0.001 μM Compound: Efavirenz	Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	IC₅₀	0.002 μM Compound: Efavirenz	Anti-HIV-1 activity against K1001 strain was determined in MT-4 cells by the MTT method Anti-HIV-1 activity against K1001 strain was determined in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	IC₅₀	0.04 μM Compound: Efavirenz	Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	IC₅₀	0.04 μM Compound: Efavirenz	Anti-HIV-1 activity against K103N+Y181C strain was determined in MT-4 cells by the MTT method Anti-HIV-1 activity against K103N+Y181C strain was determined in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	IC₅₀	0.04 μM Compound: Efavirenz	Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	IC₅₀	0.2 μM Compound: Efavirenz	Anti-HIV-1 activity against Y188L strain was determined in MT-4 cells by the MTT method Anti-HIV-1 activity against Y188L strain was determined in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	EC₅₀	0.004 μM Compound: Efavirenz	Effective dose required to achieve protection of MT-4 cells from wild type IIIB HIV-1 induced cytopathogenicity Effective dose required to achieve protection of MT-4 cells from wild type IIIB HIV-1 induced cytopathogenicity	[PMID: 14761194]
MT4	EC₅₀	0.025 μM Compound: Efavirenz	Effective dose required to achieve protection of MT-4 cells from Y181C HIV-1 induced cytopathogenicity Effective dose required to achieve protection of MT-4 cells from Y181C HIV-1 induced cytopathogenicity	[PMID: 14761194]
MT4	IC₅₀	2.7 nM Compound: Efavirenz	Antiviral activity against MT-4 cells infected with Nev-R strain of HIV-1 Antiviral activity against MT-4 cells infected with Nev-R strain of HIV-1	[PMID: 14971897]
MT4	IC₅₀	3.5 nM Compound: Efavirenz	Antiviral activity against MT-4 cells infected with wild-type HIV-1 Antiviral activity against MT-4 cells infected with wild-type HIV-1	[PMID: 14971897]
MT4	IC₅₀	0.04 μM Compound: Efavirenz (ref 18)	Potency against non nucleoside reverse transcriptor was determined in MT-4 cells Potency against non nucleoside reverse transcriptor was determined in MT-4 cells	[PMID: 15109677]
MT4	CC₅₀	80 μM Compound: Efavirenz	Cytotoxic concentration that reduces the MT-4 cell viability by 50% Cytotoxic concentration that reduces the MT-4 cell viability by 50%	[PMID: 15149669]
MT4	IC₅₀	0.004 μM Compound: Efavirenz	Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells	[PMID: 15149669]
MT4	CC₅₀	35 μM Compound: Efavirenz (EFV)	In vitro cytotoxicity against mock infected MT-4 cells. In vitro cytotoxicity against mock infected MT-4 cells.	[PMID: 15239667]
MT4	EC₅₀	0.004 μM Compound: Efavirenz (EFV)	Inhibition of HIV-1 (IIIB) induced cytopathicity in MT-4 cells. Inhibition of HIV-1 (IIIB) induced cytopathicity in MT-4 cells.	[PMID: 15239667]
MT4	EC₅₀	0.025 μM Compound: Efavirenz (EFV)	Inhibition of Efavirenz resistant HIV-1 (Y181C) induced cytopathicity in MT-4 cells. Inhibition of Efavirenz resistant HIV-1 (Y181C) induced cytopathicity in MT-4 cells.	[PMID: 15239667]
MT4	EC₅₀	0.15 μM Compound: Efavirenz (EFV)	Inhibition of Efavirenz resistant HIV-1 (K103N-Y181C) induced cytopathicity in MT-4 cells. Inhibition of Efavirenz resistant HIV-1 (K103N-Y181C) induced cytopathicity in MT-4 cells.	[PMID: 15239667]
MT4	EC₅₀	0.004 μM Compound: Efavirenz	Concentration required for 50% protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity was determined by the MTT method Concentration required for 50% protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity was determined by the MTT method	[PMID: 15634015]
MT4	EC₅₀	0.004 μM Compound: 3	Protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity Protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity	[PMID: 15634015]
MT4	EC₅₀	0.025 μM Compound: Efavirenz	Compound concentration required to achieve 50% protection of infected MT-4 cells from Y181C strain was determined by the MTT method Compound concentration required to achieve 50% protection of infected MT-4 cells from Y181C strain was determined by the MTT method	[PMID: 15634015]
MT4	EC₅₀	0.025 μM Compound: 3	Concentration required to achieve 50% protection of infected MT-4 cells from Y181C-HIV-1 strain Concentration required to achieve 50% protection of infected MT-4 cells from Y181C-HIV-1 strain	[PMID: 15634015]
MT4	EC₅₀	0.15 μM Compound: Efavirenz	Compound concentration required to achieve 50% protection of infected MT-4 cells from K103N-Y181C strain was determined by the MTT method Compound concentration required to achieve 50% protection of infected MT-4 cells from K103N-Y181C strain was determined by the MTT method	[PMID: 15634015]
MT4	EC₅₀	0.15 μM Compound: 3	Concentration required to achieve 50% protection of infected MT-4 cells from K103N-Y181C Concentration required to achieve 50% protection of infected MT-4 cells from K103N-Y181C	[PMID: 15634015]
MT4	EC₅₀	>10 μM Compound: Efavirenz	Effective concentration of the compound to inhibit HIV-1 mutant L100I+K103N replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant L100I+K103N replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	0.001 μM Compound: Efavirenz	Effective concentration of the compound to inhibit HIV-1 mutant LAI replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant LAI replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	0.002 μM Compound: Efavirenz	Effective concentration of the compound to inhibit HIV-1 mutant Y181C replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant Y181C replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	0.04 μM Compound: Efavirenz	Effective concentration of the compound to inhibit HIV-1 mutant K103N replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant K103N replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	0.04 μM Compound: Efavirenz	Effective concentration of the compound to inhibit HIV-1 mutant K103N+Y181C replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant K103N+Y181C replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	0.04 μM Compound: Efavirenz	Effective concentration of the compound to inhibit HIV-1 mutant L100I replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant L100I replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	0.16 μM Compound: Efavirenz	Effective concentration of the compound to inhibit HIV-1 mutant Y188L replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant Y188L replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	CC₅₀	>0.32 μM Compound: EVZ	Cytotoxicity against MT4 cells by MTT method Cytotoxicity against MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	0.001 μM Compound: EVZ	Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	0.057 μM Compound: EVZ	Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	0.2 μM Compound: EVZ	Antiviral activity against HIV1 IRLL98 mutant strain infected MT4 cells by MTT method Antiviral activity against HIV1 IRLL98 mutant strain infected MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	0.3 μM Compound: EVZ	Antiviral activity against HIV1 Y188L mutant strain infected MT4 cells by MTT method Antiviral activity against HIV1 Y188L mutant strain infected MT4 cells by MTT method	[PMID: 16335924]
MT4	CC₅₀	>0.32 μM Compound: Efavirenz	Cytotoxicity against MT4 cells by MTT assay Cytotoxicity against MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	0.001 μM Compound: Efavirenz	Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	0.057 μM Compound: Efavirenz	Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	0.2 μM Compound: Efavirenz	Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	0.3 μM Compound: Efavirenz	Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	0.004 μM Compound: EFV	Antiviral activity against HIV1 3B in MT4 cell line Antiviral activity against HIV1 3B in MT4 cell line	[PMID: 16722636]
MT4	IC₅₀	42 nM Compound: EFV	Inhibition of reverse transcriptase activity in HIV1 NL4-3 infected MT4 cells before dialysis Inhibition of reverse transcriptase activity in HIV1 NL4-3 infected MT4 cells before dialysis	[PMID: 17116672]
MT4	IC₅₀	60 nM Compound: EFV	Inhibition of reverse transcriptase activity in HIV1 NL4-3 infected MT4 cells after dialysis Inhibition of reverse transcriptase activity in HIV1 NL4-3 infected MT4 cells after dialysis	[PMID: 17116672]
MT4	IC₅₀	1 nM Compound: EFV, efavirenz	Antiviral activity against HIV1 LAI assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method Antiviral activity against HIV1 LAI assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method	[PMID: 17157017]
MT4	IC₅₀	1.99 nM Compound: EFV, efavirenz	Antiviral activity against HIV1 RT 181C mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method Antiviral activity against HIV1 RT 181C mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method	[PMID: 17157017]
MT4	IC₅₀	1000 nM Compound: EFV, efavirenz	Antiviral activity against HIV1 RT 100I/103N mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method Antiviral activity against HIV1 RT 100I/103N mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method	[PMID: 17157017]
MT4	IC₅₀	158 nM Compound: EFV, efavirenz	Antiviral activity against HIV1 RT 188L mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method Antiviral activity against HIV1 RT 188L mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method	[PMID: 17157017]
MT4	IC₅₀	3.98 nM Compound: EFV, efavirenz	Antiviral activity against HIV1 RT 100I mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method Antiviral activity against HIV1 RT 100I mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method	[PMID: 17157017]
MT4	IC₅₀	39.8 nM Compound: EFV, efavirenz	Antiviral activity against HIV1 RT 103N/181C mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method Antiviral activity against HIV1 RT 103N/181C mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method	[PMID: 17157017]
MT4	IC₅₀	39.8 nM Compound: EFV, efavirenz	Antiviral activity against HIV1 with RT 103N mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method Antiviral activity against HIV1 with RT 103N mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method	[PMID: 17157017]
MT4	CC₅₀	32314 nM Compound: 13, efavirenz	Cytotoxicity against human MT4 cells after 3 days by EGFP based replication assay Cytotoxicity against human MT4 cells after 3 days by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	1.6 nM Compound: 13, efavirenz	Antiviral activity against wild type HIV1 LAI infected in MT4 cells by EGFP based replication assay Antiviral activity against wild type HIV1 LAI infected in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	1460 nM Compound: 13, efavirenz	Antiviral activity against HIV1 LAI with RT L100I and K103N mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT L100I and K103N mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	3.9 nM Compound: 13, efavirenz	Antiviral activity against HIV1 LAI with RT Y181C mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT Y181C mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	31 nM Compound: 13, efavirenz	Antiviral activity against HIV1 LAI with RT L100I mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT L100I mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	4.1 nM Compound: 13, efavirenz	Antiviral activity against HIV1 LAI with RT F227C and V106A mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT F227C and V106A mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	46.4 nM Compound: 13, efavirenz	Antiviral activity against HIV1 LAI with RT K103N mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT K103N mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	46.9 nM Compound: 13, efavirenz	Antiviral activity against HIV1 LAI with RT F227C mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT F227C mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	55 nM Compound: 13, efavirenz	Antiviral activity against HIV1 LAI with RT K103N and Y181C mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT K103N and Y181C mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	55 nM Compound: 13, efavirenz	Antiviral activity against HIV1 LAI with RT Y188L mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT Y188L mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	CC₅₀	>6 μM Compound: efavirenz	Cytotoxicity against MT4 cells assessed as reduction of cell viability Cytotoxicity against MT4 cells assessed as reduction of cell viability	[PMID: 17276064]
MT4	EC₅₀	0.0009 μM Compound: efavirenz	Antiviral activity against HIV1 assessed as reduction of virus-induced cytopathic effect in MT4 cells Antiviral activity against HIV1 assessed as reduction of virus-induced cytopathic effect in MT4 cells	[PMID: 17276064]
MT4	CC₅₀	6 μM Compound: efavirenz	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 17803290]
MT4	EC₅₀	0.001 μM Compound: efavirenz	Antiviral activity against HIV1 3B in human MT4 cells by XTT assay Antiviral activity against HIV1 3B in human MT4 cells by XTT assay	[PMID: 17803290]
MT4	ED₅₀	10 nM Compound: EFV	Antiviral activity against HIV1 RT Y181C mutant in MT4 cells by MTT assay Antiviral activity against HIV1 RT Y181C mutant in MT4 cells by MTT assay	[PMID: 17803291]
MT4	ED₅₀	200 nM Compound: EFV	Antiviral activity against HIV1 RT K103N-Y181C mutant in MT4 cells by MTT assay Antiviral activity against HIV1 RT K103N-Y181C mutant in MT4 cells by MTT assay	[PMID: 17803291]
MT4	ED₅₀	3 nM Compound: EFV	Antiviral activity against HIV1 3B in MT4 cells by MTT assay Antiviral activity against HIV1 3B in MT4 cells by MTT assay	[PMID: 17803291]
MT4	CC₅₀	30 μM Compound: efavirenz	Protection against HIV1 HTLV 3B-induced cytopathogenicity in human MT4 cells by MTT assay Protection against HIV1 HTLV 3B-induced cytopathogenicity in human MT4 cells by MTT assay	[PMID: 17904371]
MT4	CC₅₀	>0.3 μM Compound: EFV, efavirenz	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17910429]
MT4	EC₅₀	>10 μM Compound: EFV, efavirenz	Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	[PMID: 17910429]
MT4	EC₅₀	0.004 μM Compound: EFV, efavirenz	Antiviral activity against HIV1 NL43 in MT4 cells assessed as inhibition of viral induced cytopathic effect after 4 days by MTT method Antiviral activity against HIV1 NL43 in MT4 cells assessed as inhibition of viral induced cytopathic effect after 4 days by MTT method	[PMID: 17910429]
MT4	EC₅₀	0.006 μM Compound: EFV, efavirenz	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	[PMID: 17910429]
MT4	EC₅₀	0.08 μM Compound: EFV, efavirenz	Antiviral activity against HIV1 with reverse transcriptase IRLL98 mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method Antiviral activity against HIV1 with reverse transcriptase IRLL98 mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	[PMID: 17910429]
MT4	EC₅₀	0.09 μM Compound: EFV, efavirenz	Antiviral activity against HIV1 with reverse transcriptase K103N mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method Antiviral activity against HIV1 with reverse transcriptase K103N mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	[PMID: 17910429]
MT4	EC₅₀	0.7 nM Compound: 1	Antiviral activity against HIV1 in MT4 cells Antiviral activity against HIV1 in MT4 cells	[PMID: 18083512]
MT4	EC₅₀	0.01 μM Compound: efavirenz	Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay	[PMID: 18226532]
MT4	EC₅₀	0.04 μM Compound: efavirenz	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay	[PMID: 18226532]
MT4	EC₅₀	0.01 μM Compound: table 6,efavirenz	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 18226533]
MT4	EC₅₀	0.04 μM Compound: table 6,efavirenz	Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 18226533]
MT4	CC₅₀	>6.34 μM Compound: efavirenz	Cytotoxicity against human MT4 cells Cytotoxicity against human MT4 cells	[PMID: 18267363]
MT4	EC₅₀	0.003 μM Compound: efavirenz	Antiviral activity against HIV1 3B infected in MT4 cells by MTT Antiviral activity against HIV1 3B infected in MT4 cells by MTT	[PMID: 18267363]
MT4	EC₅₀	0.38 μM Compound: efavirenz	Antiviral activity against HIV1 RES056 infected in MT4 cells by MTT Antiviral activity against HIV1 RES056 infected in MT4 cells by MTT	[PMID: 18267363]
MT4	EC₅₀	>31.68 μM Compound: Efavirenz	Antiretroviral activity against Human immunodeficiency virus 2 EHO infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Human immunodeficiency virus 2 EHO infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	>31.68 μM Compound: Efavirenz	Antiretroviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	>31.68 μM Compound: Efavirenz	Antiretroviral activity against Simian immunodeficiency virus MAC 251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Simian immunodeficiency virus MAC 251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.00095 μM Compound: Efavirenz	Antiviral activity against Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.0016 μM Compound: Efavirenz	Antiviral activity against Protease inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against Protease inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.0019 μM Compound: Efavirenz	Antiretroviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.015 μM Compound: Efavirenz	Antiretroviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiretroviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	EC₅₀	0.086 μM Compound: Efavirenz	Antiviral activity against non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18541726]
MT4	CC₅₀	>6 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells Cytotoxicity against human MT4 cells	[PMID: 18585918]
MT4	EC₅₀	0.0009 μM Compound: Efavirenz	Antiviral activity against HIV1 3B in human MT4 cells assessed as virus-induced cytopathogenicity after 5 days Antiviral activity against HIV1 3B in human MT4 cells assessed as virus-induced cytopathogenicity after 5 days	[PMID: 18585918]
MT4	CC₅₀	>3 μM Compound: EFZ	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18630898]
MT4	EC₅₀	0.007 μM Compound: EFZ	Antiviral activity against HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 18630898]
MT4	EC₅₀	0.044 μM Compound: EFZ	Antiviral activity against HIV1 isolates with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 isolates with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 18630898]
MT4	EC₅₀	0.39 μM Compound: EFZ	Antiviral activity against HIV1 isolates with reverse transcriptase K103N mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 isolates with reverse transcriptase K103N mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 18630898]
MT4	EC₅₀	1.57 μM Compound: EFZ	Antiviral activity against HIV1 isolates with reverse transcriptase Y188L mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 isolates with reverse transcriptase Y188L mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 18630898]
MT4	EC₅₀	>0.5 μM Compound: efavirenz	Antiviral activity against HIV1 with reverse transcriptase K103N/L100I mutation in human MT4 cells assessed as reduction of virus-induced cytopathic effect Antiviral activity against HIV1 with reverse transcriptase K103N/L100I mutation in human MT4 cells assessed as reduction of virus-induced cytopathic effect	[PMID: 18632268]
MT4	EC₅₀	0.006 μM Compound: efavirenz	Antiviral activity against HIV1 with reverse transcriptase G190A mutation in human MT4 cells assessed as reduction of virus-induced cytopathic effect Antiviral activity against HIV1 with reverse transcriptase G190A mutation in human MT4 cells assessed as reduction of virus-induced cytopathic effect	[PMID: 18632268]
MT4	EC₅₀	0.019 μM Compound: efavirenz	Antiviral activity against HIV1 in human MT4 cells assessed as reduction of viral-induced cytopathic effect in presence of human serum Antiviral activity against HIV1 in human MT4 cells assessed as reduction of viral-induced cytopathic effect in presence of human serum	[PMID: 18632268]
MT4	EC₅₀	0.083 μM Compound: efavirenz	Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathic effect Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathic effect	[PMID: 18632268]
MT4	CC₅₀	>6.336 μM Compound: EFV	Cytotoxicity against human MT4 cells Cytotoxicity against human MT4 cells	[PMID: 18824350]
MT4	EC₅₀	0.0044 μM Compound: EFV	Antiviral activity against HIV1 3B in human MT4 cells assessed as protection of cell against virus-induced cytopathogenicity Antiviral activity against HIV1 3B in human MT4 cells assessed as protection of cell against virus-induced cytopathogenicity	[PMID: 18824350]
MT4	ED₅₀	0.001 μM Compound: EFV	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as virus-induced cell death by MTT method Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as virus-induced cell death by MTT method	[PMID: 18842407]
MT4	ED₅₀	0.008 μM Compound: EFV	Antiviral activity against drug-resistant HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method Antiviral activity against drug-resistant HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method	[PMID: 18842407]
MT4	ED₅₀	0.133 μM Compound: EFV	Antiviral activity against drug-resistant HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method Antiviral activity against drug-resistant HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method	[PMID: 18842407]
MT4	EC₅₀	0.02 μM Compound: EFV	Antiviral activity against HIV1 3B Y181C resistant mutant in human MT4 cells assessed as protection against viral induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B Y181C resistant mutant in human MT4 cells assessed as protection against viral induced cytopathogenicity by MTT assay	[PMID: 18954921]
MT4	EC₅₀	<1 nM Compound: EFV	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 236L mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 236L mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	EC₅₀	>100 nM Compound: EFV	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 190S mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 190S mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	EC₅₀	1 nM Compound: EFV	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 225H mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 225H mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	EC₅₀	1 nM Compound: EFV	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 227L mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 227L mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	EC₅₀	12 nM Compound: EFV	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 101E mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 101E mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	EC₅₀	18 nM Compound: EFV	Antiviral activity against wild type HIV HXB2 in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay in presence of 40% human serum Antiviral activity against wild type HIV HXB2 in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay in presence of 40% human serum	[PMID: 19007201]
MT4	EC₅₀	2 nM Compound: EFV	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 138K mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 138K mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	EC₅₀	2 nM Compound: EFV	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 181I mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 181I mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	EC₅₀	3 nM Compound: EFV	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 108I mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 108I mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	EC₅₀	3 nM Compound: EFV	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 181C mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 181C mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	EC₅₀	4 nM Compound: EFV	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 188H mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 188H mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	EC₅₀	6 nM Compound: EFV	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 106A mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 106A mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	EC₅₀	6 nM Compound: EFV	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 190A mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 190A mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	EC₅₀	66 nM Compound: EFV	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 103N mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 103N mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	EC₅₀	7 nM Compound: EFV	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 100I mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 100I mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	EC₅₀	8 nM Compound: EFV	Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 179D mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 179D mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay	[PMID: 19007201]
MT4	EC₅₀	0.01 μM Compound: Efavirenz	Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 19058881]
MT4	CC₅₀	>0.32 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 19140683]
MT4	EC₅₀	0.001 μM Compound: Efavirenz	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells after 5 days by MTT assay Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells after 5 days by MTT assay	[PMID: 19140683]
MT4	EC₅₀	0.003 μM Compound: Efavirenz	Antiviral activity against HIV1 reverse transcriptase Y188L mutant infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 reverse transcriptase Y188L mutant infected in human MT4 cells after 5 days by MTT assay	[PMID: 19140683]
MT4	EC₅₀	0.008 μM Compound: Efavirenz	Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT4 cells after 5 days by MTT assay	[PMID: 19140683]
MT4	EC₅₀	0.057 μM Compound: Efavirenz	Antiviral activity against HIV1 reverse transcriptase K103N mutant infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 reverse transcriptase K103N mutant infected in human MT4 cells after 5 days by MTT assay	[PMID: 19140683]
MT4	EC₅₀	>10 μM Compound: efavirenz	Antiviral activity against HIV1 NL4-3 with double K103N/L100I mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay Antiviral activity against HIV1 NL4-3 with double K103N/L100I mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay	[PMID: 19469474]
MT4	EC₅₀	0.003 μM Compound: efavirenz	Antiviral activity against wild type HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay Antiviral activity against wild type HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay	[PMID: 19469474]
MT4	EC₅₀	0.004 μM Compound: efavirenz	Antiviral activity against HIV1 NL4-3 with Y181C mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay Antiviral activity against HIV1 NL4-3 with Y181C mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay	[PMID: 19469474]
MT4	EC₅₀	0.167 μM Compound: efavirenz	Antiviral activity against HIV1 NL4-3 with L100I mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay Antiviral activity against HIV1 NL4-3 with L100I mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay	[PMID: 19469474]
MT4	EC₅₀	0.32 μM Compound: efavirenz	Antiviral activity against HIV1 NL4-3 with K103N mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay Antiviral activity against HIV1 NL4-3 with K103N mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay	[PMID: 19469474]
MT4	CC₅₀	>6 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells after 5 days Cytotoxicity against human MT4 cells after 5 days	[PMID: 19616956]
MT4	EC₅₀	0.0009 μM Compound: Efavirenz	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days	[PMID: 19616956]
MT4	CC₅₀	>6.336 μM Compound: EFV	Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay	[PMID: 19628308]
MT4	EC₅₀	0.0044 μM Compound: EFV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay	[PMID: 19628308]
MT4	CC₅₀	>6.336 μM Compound: EFV	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 19643613]
MT4	EC₅₀	0.0044 μM Compound: EFV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay	[PMID: 19643613]
MT4	IC₅₀	1 nM Compound: EFV	Antiviral activity against HIV-1 LAI harboring wild type reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV-1 LAI harboring wild type reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	1.99 nM Compound: EFV	Antiviral activity against HIV1 HXB2 harboring 138K mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 138K mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	1.99 nM Compound: EFV	Antiviral activity against HIV1 HXB2 harboring Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	10 nM Compound: EFV	Antiviral activity against HIV1 HXB2 harboring 190A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 190A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	1000 nM Compound: EFV	Antiviral activity against HIV1 HXB2 harboring 100I and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 100I and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	158 nM Compound: EFV	Antiviral activity against HIV1 HXB2 harboring 101E and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 101E and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	158 nM Compound: EFV	Antiviral activity against HIV1 HXB2 harboring 227C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 227C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	158 nM Compound: EFV	Antiviral activity against HIV1 HXB2 harboring Y188L mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring Y188L mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	25.1 nM Compound: EFV	Antiviral activity against HIV1 HXB2 harboring 227L and 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 227L and 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	251 nM Compound: EFV	Antiviral activity against HIV1 HXB2 harboring 190S mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 190S mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	3.98 nM Compound: EFV	Antiviral activity against HIV1 HXB2 harboring 100I mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 100I mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	39.8 nM Compound: EFV	Antiviral activity against HIV1 HXB2 harboring 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	39.8 nM Compound: EFV	Antiviral activity against HIV1 HXB2 harboring K103N and Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring K103N and Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	39.8 nM Compound: EFV	Antiviral activity against HIV1 HXB2 harboring K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	5.01 nM Compound: EFV	Antiviral activity against HIV1 HXB2 harboring 179E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 179E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	6.3 nM Compound: EFV	Antiviral activity against HIV1 HXB2 harboring 101E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 101E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	CC₅₀	45 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay	[PMID: 19775780]
MT4	EC₅₀	0.002 μM Compound: EFV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19775780]
MT4	EC₅₀	0.01 μM Compound: EFV	Antiviral activity against NNRTI-resistant HIV1 N119 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against NNRTI-resistant HIV1 N119 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19775780]
MT4	EC₅₀	0.06 μM Compound: EFV	Antiviral activity against NNRTI-resistant HIV1 A17 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against NNRTI-resistant HIV1 A17 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19775780]
MT4	EC₅₀	7 μM Compound: EFV	Antiviral activity against HIV1 EFV with reverse transcriptase K103R, V179D, P225H mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 EFV with reverse transcriptase K103R, V179D, P225H mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19775780]
MT4	CC₅₀	35 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 96 hrs by MTT assay Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 96 hrs by MTT assay	[PMID: 19781821]
MT4	EC₅₀	0.003 μM Compound: EFV	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus induced cytopathogenicity after 4 days by MTT assay	[PMID: 19781821]
MT4	EC₅₀	0.31 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype C infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype C infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	0.31 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype G infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype G infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	0.49 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype (H) infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype (H) infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	0.53 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype AE infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype AE infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	0.53 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype AG infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype AG infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	0.66 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype F1 infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype F1 infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	0.7 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype BG infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype BG infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	0.72 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype A1 infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype A1 infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	1.19 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype D infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype D infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	1.73 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	24.83 μM Compound: EFV	Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	CC₅₀	>6 μM Compound: Efavirenz	Cytotoxicity in human MT4 cells assessed as reduction in cell viability Cytotoxicity in human MT4 cells assessed as reduction in cell viability	[PMID: 20097079]
MT4	EC₅₀	0.0009 μM Compound: Efavirenz	Antiviral activity against HIV1 3B infected in human MT4 cells assessed inhibition of viral-induced cytopathic effect after 5 days Antiviral activity against HIV1 3B infected in human MT4 cells assessed inhibition of viral-induced cytopathic effect after 5 days	[PMID: 20097079]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 20307984]
MT4	EC₅₀	0.003 μM Compound: EFV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20307984]
MT4	EC₅₀	0.18 μM Compound: EFV	Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20307984]
MT4	IC₅₀	>1000 nM Compound: Efavirenz	Antiviral activity against HIV1 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against HIV1 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 20538456]
MT4	IC₅₀	>500 nM Compound: Efavirenz	Antiviral activity against HIV1 expressing reverse transcriptase K103N/L100I double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against HIV1 expressing reverse transcriptase K103N/L100I double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 20538456]
MT4	IC₅₀	1.8 nM Compound: Efavirenz	Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect in presence of 10 % fetal bovine serum Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect in presence of 10 % fetal bovine serum	[PMID: 20538456]
MT4	IC₅₀	18.1 nM Compound: Efavirenz	Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect in presence of 40 % human serum Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect in presence of 40 % human serum	[PMID: 20538456]
MT4	IC₅₀	5.7 nM Compound: Efavirenz	Antiviral activity against HIV1 expressing reverse transcriptase V106A mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against HIV1 expressing reverse transcriptase V106A mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 20538456]
MT4	IC₅₀	6 nM Compound: Efavirenz	Antiviral activity against HIV1 expressing reverse transcriptase G190A mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against HIV1 expressing reverse transcriptase G190A mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 20538456]
MT4	CC₅₀	>63.36 μM Compound: EFV	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 20570527]
MT4	EC₅₀	0.003 μM Compound: EFV	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 20570527]
MT4	EC₅₀	0.56 μM Compound: EFV	Antiviral activity against HIV1 bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 20570527]
MT4	EC₅₀	0.11 μM Compound: EFV	Antiviral activity against HIV1 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	104 nM Compound: EFV	Antiviral activity against HIV1 with reverse transcriptase F227L, V106A mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase F227L, V106A mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	2.1 nM Compound: EFV	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	2.2 nM Compound: EFV	Antiviral activity against wild type HIV1 LAI infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type HIV1 LAI infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	222 nM Compound: EFV	Antiviral activity against HIV1 with reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	32 nM Compound: EFV	Antiviral activity against HIV1 with reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	5.4 nM Compound: EFV	Antiviral activity against HIV1 with reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	5.7 nM Compound: EFV	Antiviral activity against HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	66 nM Compound: EFV	Antiviral activity against HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	CC₅₀	≥6.3 μM Compound: EFV	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 20598556]
MT4	IC₅₀	>100 nM Compound: Efavirenz	Antiviral activity against HIV1 harboring reverse transcriptase K103N/L100I double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS Antiviral activity against HIV1 harboring reverse transcriptase K103N/L100I double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS	[PMID: 20829038]
MT4	IC₅₀	>100 nM Compound: Efavirenz	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS	[PMID: 20829038]
MT4	IC₅₀	1.8 nM Compound: Efavirenz	Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS	[PMID: 20829038]
MT4	IC₅₀	18.1 nM Compound: Efavirenz	Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 40% human serum Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 40% human serum	[PMID: 20829038]
MT4	IC₅₀	5.7 nM Compound: Efavirenz	Antiviral activity against HIV1 harboring reverse transcriptase V106A mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS Antiviral activity against HIV1 harboring reverse transcriptase V106A mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS	[PMID: 20829038]
MT4	IC₅₀	82.8 nM Compound: Efavirenz	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS	[PMID: 20829038]
MT4	CC₅₀	3167.8 nM Compound: EFV	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 21438533]
MT4	EC₅₀	10.1 nM Compound: EFV	Antiviral activity against HIV 1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV 1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 21438533]
MT4	EC₅₀	1615 nM Compound: EFV	Antiviral activity against HIV 1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV 1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 21438533]
MT4	EC₅₀	3.17 nM Compound: EFV	Antiviral activity against wild type HIV 1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV 1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 21438533]
MT4	EC₅₀	343.4 nM Compound: EFV	Antiviral activity against HIV 1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV 1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 21438533]
MT4	EC₅₀	633.5 nM Compound: EFV	Antiviral activity against multidrug-resistant HIV 1 IRLL98 harboring reverse transcriptase K101Q/Y181C/G190a mutant infected in human MT4 cells assessed as virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against multidrug-resistant HIV 1 IRLL98 harboring reverse transcriptase K101Q/Y181C/G190a mutant infected in human MT4 cells assessed as virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 21438533]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay	[PMID: 21683601]
MT4	EC₅₀	0.0044 μM Compound: EFV	Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 21683601]
MT4	CC₅₀	>6.33 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 21824782]
MT4	EC₅₀	0.005 μM Compound: Efavirenz	Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 21824782]
MT4	EC₅₀	0.443 μM Compound: Efavirenz	Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 21824782]
MT4	EC₅₀	0.0055 μM Compound: EFV	Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.054 μM Compound: EFV	Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.108 μM Compound: EFV	Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	CC₅₀	>63 μM Compound: Efavirenz, Sustiva	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 21903401]
MT4	EC₅₀	0.003 μM Compound: Efavirenz, Sustiva	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 21903401]
MT4	EC₅₀	0.56 μM Compound: Efavirenz, Sustiva	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 21903401]
MT4	CC₅₀	>6.34 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells measured by MTT assay Cytotoxicity against human MT4 cells measured by MTT assay	[PMID: 22037050]
MT4	EC₅₀	0.0054 μM Compound: Efavirenz	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22037050]
MT4	EC₅₀	0.51 μM Compound: Efavirenz	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22037050]
MT4	CC₅₀	40 μM Compound: EFV	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 22047799]
MT4	EC₅₀	0.002 μM Compound: EFV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 22047799]
MT4	EC₅₀	0.0014 μM Compound: Efavirenz	Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of viral infection Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of viral infection	[PMID: 22081993]
MT4	EC₅₀	0.002 μM Compound: Efavirenz	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral infection Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral infection	[PMID: 22081993]
MT4	EC₅₀	0.037 μM Compound: Efavirenz	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase K103N and Y181C double mutant infected in human MT4 cells assessed as inhibition of viral infection Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase K103N and Y181C double mutant infected in human MT4 cells assessed as inhibition of viral infection	[PMID: 22081993]
MT4	CC₅₀	>6.3 μM Compound: EFV	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22405288]
MT4	EC₅₀	0.57 μM Compound: EFV	Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 22405288]
MT4	EC₅₀	5.4 nM Compound: EFV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 22405288]
MT4	CC₅₀	3200 nM Compound: EFV	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22428851]
MT4	EC₅₀	10 nM Compound: EFV	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22428851]
MT4	EC₅₀	1600 nM Compound: EFV	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22428851]
MT4	EC₅₀	340 nM Compound: EFV	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22428851]
MT4	EC₅₀	7.3 nM Compound: EFV	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22428851]
MT4	CC₅₀	40 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 22513121]
MT4	EC₅₀	0.002 μM Compound: Efavirenz	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 22513121]
MT4	CC₅₀	>6.3 μM Compound: EFV	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22575532]
MT4	EC₅₀	0.005 μM Compound: EFV	Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22575532]
MT4	EC₅₀	0.44 μM Compound: EFV	Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22575532]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22591854]
MT4	EC₅₀	0.55 μM Compound: EFV	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22591854]
MT4	EC₅₀	6.57 nM Compound: EFV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22591854]
MT4	CC₅₀	>1 μg/mL Compound: EFV	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22652226]
MT4	EC₅₀	0.003 μM Compound: EFV	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days	[PMID: 22652226]
MT4	CC₅₀	>15839 nM Compound: EFV	Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay	[PMID: 22712652]
MT4	EC₅₀	157.5 nM Compound: EFV	Antiviral activity against HIV1 containing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 containing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	EC₅₀	315 nM Compound: EFV	Antiviral activity against HIV1 containing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 containing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	EC₅₀	6.3 nM Compound: EFV	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	EC₅₀	69.3 nM Compound: EFV	Antiviral activity against HIV1 containing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 containing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	EC₅₀	980 nM Compound: EFV	Antiviral activity against HIV1 IRLL98 containing reverse transcriptase K101Q, Y181C and G190A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 IRLL98 containing reverse transcriptase K101Q, Y181C and G190A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	CC₅₀	>6.3 μM Compound: EFV	Cytotoxicity against mock-infected human MT4 cells by MTT assay Cytotoxicity against mock-infected human MT4 cells by MTT assay	[PMID: 22883027]
MT4	EC₅₀	0.55 μM Compound: EFV	Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	[PMID: 22883027]
MT4	EC₅₀	6.6 μM Compound: EFV	Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	[PMID: 22883027]
MT4	CC₅₀	37 μM Compound: EFV	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 22884523]
MT4	EC₅₀	0.002 μM Compound: EFV	Antiviral activity against HIV1 infected in human MT4 cells assessed as virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 infected in human MT4 cells assessed as virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 22884523]
MT4	CC₅₀	>6.3 μM Compound: EFV	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 23084898]
MT4	EC₅₀	0.005 μM Compound: EFV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	[PMID: 23084898]
MT4	EC₅₀	0.57 μM Compound: EFV	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	[PMID: 23084898]
MT4	CC₅₀	>6.3 μM Compound: EFV	Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay	[PMID: 23098609]
MT4	CC₅₀	>6.3 μM Compound: EFV	Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay	[PMID: 23098609]
MT4	EC₅₀	0.005 μM Compound: EFV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 23098609]
MT4	EC₅₀	0.5 nM Compound: EFV	Antiviral activity against HIV1 expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay Antiviral activity against HIV1 expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay	[PMID: 23137340]
MT4	EC₅₀	1 nM Compound: EFV	Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay	[PMID: 23137340]
MT4	EC₅₀	157 nM Compound: EFV	Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay	[PMID: 23137340]
MT4	EC₅₀	20 nM Compound: EFV	Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay	[PMID: 23137340]
MT4	CC₅₀	>2 μM Compound: EFV	Cytotoxicity against mock-infected human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 23415090]
MT4	EC₅₀	0.007 μM Compound: EFV	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	[PMID: 23415090]
MT4	EC₅₀	0.02 μM Compound: EFV	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	[PMID: 23415090]
MT4	EC₅₀	0.59 μM Compound: EFV	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	[PMID: 23415090]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 23707918]
MT4	EC₅₀	>6.34 μM Compound: EFV	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23707918]
MT4	EC₅₀	0.01 μM Compound: EFV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23707918]
MT4	EC₅₀	0.51 μM Compound: EFV	Antiviral activity against HIV1 RES056 expressing RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23707918]
MT4	CC₅₀	6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 24055077]
MT4	EC₅₀	0.0067 μM Compound: EFV	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24055077]
MT4	EC₅₀	0.46 μM Compound: EFV	Antiviral activity against HIV-1 RESO56 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV-1 RESO56 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24055077]
MT4	CC₅₀	6.3 μM Compound: EFV	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 24134904]
MT4	EC₅₀	0.009 μM Compound: EFV	Antiviral activity against wild-type HIV1 3B infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild-type HIV1 3B infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24134904]
MT4	EC₅₀	0.52 μM Compound: EFV	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24134904]
MT4	CC₅₀	>6.3 μM Compound: EFV	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 24239481]
MT4	EC₅₀	0.007 μM Compound: EFV	Antiviral activity against HIV1 3B infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	[PMID: 24239481]
MT4	EC₅₀	0.52 μM Compound: EFV	Antiviral activity against drug-resistant HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay Antiviral activity against drug-resistant HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	[PMID: 24239481]
MT4	CC₅₀	>6.3 μM Compound: EFV, DMP266	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 24275349]
MT4	EC₅₀	0.0074 μM Compound: EFV, DMP266	Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay	[PMID: 24275349]
MT4	EC₅₀	0.52 μM Compound: EFV, DMP266	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay	[PMID: 24275349]
MT4	CC₅₀	>6.34 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells assessed as cell viability Cytotoxicity against human MT4 cells assessed as cell viability	[PMID: 24457088]
MT4	EC₅₀	0.006 μM Compound: Efavirenz	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days	[PMID: 24457088]
MT4	CC₅₀	45 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 24489455]
MT4	EC₅₀	0.002 μM Compound: Efavirenz	Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24489455]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay	[PMID: 24602795]
MT4	EC₅₀	0.0057 μM Compound: EFV	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24602795]
MT4	EC₅₀	0.32 μM Compound: EFV	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24602795]
MT4	CC₅₀	>6.3 μM Compound: EFV	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 24680058]
MT4	EC₅₀	0.022 μM Compound: EFV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	[PMID: 24680058]
MT4	EC₅₀	0.507 μM Compound: EFV	Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	[PMID: 24680058]
MT4	CC₅₀	>15839 nM Compound: EFV, DMP-266	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 24769348]
MT4	EC₅₀	>317 nM Compound: EFV, DMP-266	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	130 nM Compound: EFV, DMP-266	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	15.9 nM Compound: EFV, DMP-266	Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	160 nM Compound: EFV, DMP-266	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	22 nM Compound: EFV, DMP-266	Antiviral activity against HIV1 harboring reverse transcriptase L1001 mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase L1001 mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	760 nM Compound: EFV, DMP-266	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	CC₅₀	>6.3 μM Compound: 3, EFV	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 24794751]
MT4	EC₅₀	0.006 μM Compound: 3, EFV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	[PMID: 24794751]
MT4	EC₅₀	0.27 μM Compound: 3, EFV	Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	[PMID: 24794751]
MT4	CC₅₀	40 μM Compound: EFV, DMP266, L-743,726	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.002 μM Compound: EFV, DMP266, L-743,726	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.002 μM Compound: EFV, DMP266, L-743,726	Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.004 μM Compound: EFV, DMP266, L-743,726	Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.004 μM Compound: EFV, DMP266, L-743,726	Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.01 μM Compound: EFV, DMP266, L-743,726	Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.06 μM Compound: EFV, DMP266, L-743,726	Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in	[PMID: 24805780]
MT4	EC₅₀	0.08 μM Compound: EFV, DMP266, L-743,726	Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.09 μM Compound: EFV, DMP266, L-743,726	Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.1 μM Compound: EFV, DMP266, L-743,726	Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	6 μM Compound: EFV, DMP266, L-743,726	Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	7 μM Compound: EFV, DMP266, L-743,726	Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	CC₅₀	>3 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as induction of cell death by MTT method Cytotoxicity against human MT4 cells assessed as induction of cell death by MTT method	[PMID: 24933420]
MT4	EC₅₀	0.007 μM Compound: EFV	Antiviral activity against wild type HIV-1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method Antiviral activity against wild type HIV-1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	[PMID: 24933420]
MT4	EC₅₀	0.013 μM Compound: EFV	Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	[PMID: 24933420]
MT4	EC₅₀	0.34 μM Compound: EFV	Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	[PMID: 24933420]
MT4	EC₅₀	1.97 μM Compound: EFV	Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	[PMID: 24933420]
MT4	CC₅₀	6.3356 μM Compound: EFV	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 24952305]
MT4	IC₅₀	0.0226 μM Compound: EFV	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24952305]
MT4	IC₅₀	0.16 μM Compound: EFV	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24952305]
MT4	CC₅₀	40 μM Compound: EFV	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in proliferation after 96 hrs by MTT method Cytotoxicity against mock-infected human MT4 cells assessed as reduction in proliferation after 96 hrs by MTT method	[PMID: 25014745]
MT4	EC₅₀	0.002 μM Compound: EFV	Antiviral activity against HIV-13B infected in MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT method Antiviral activity against HIV-13B infected in MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT method	[PMID: 25014745]
MT4	CC₅₀	38 μM Compound: EFV	Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay	[PMID: 25082514]
MT4	EC₅₀	0.005 μM Compound: EFV	Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 25082514]
MT4	CC₅₀	>6.3 μM Compound: EFV	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 25150090]
MT4	EC₅₀	0.0053 μM Compound: EFV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	[PMID: 25150090]
MT4	EC₅₀	0.23 μM Compound: EFV	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	[PMID: 25150090]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25240095]
MT4	EC₅₀	0.0063 μM Compound: EFV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	EC₅₀	0.16 μM Compound: EFV	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	CC₅₀	>15839 nM Compound: EFV, DMP-266	Cytotoxic activity against human MT4 cells by MTT assay Cytotoxic activity against human MT4 cells by MTT assay	[PMID: 25418038]
MT4	EC₅₀	>317 nM Compound: EFV, DMP-266	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N-Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N-Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	130 nM Compound: EFV, DMP-266	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	15.9 nM Compound: EFV, DMP-266	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	160 nM Compound: EFV, DMP-266	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	22 nM Compound: EFV, DMP-266	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	760 nM Compound: EFV, DMP-266	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells after 5 days MTT assay Cytotoxicity against human MT4 cells after 5 days MTT assay	[PMID: 25537532]
MT4	EC₅₀	0.0062 μM Compound: EFV	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	EC₅₀	0.16 μM Compound: EFV	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	CC₅₀	>6.3 μM Compound: EFV	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 25626145]
MT4	EC₅₀	0.16 μM Compound: EFV	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25626145]
MT4	EC₅₀	6.3 nM Compound: EFV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25626145]
MT4	CC₅₀	>6 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability Cytotoxicity against human MT4 cells assessed as reduction in cell viability	[PMID: 25638501]
MT4	EC₅₀	0.006 μM Compound: EFV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenic effect Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenic effect	[PMID: 25638501]
MT4	CC₅₀	>6.3 μM Compound: EFV	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 25707013]
MT4	EC₅₀	0.006 μM Compound: EFV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25707013]
MT4	EC₅₀	0.16 μM Compound: EFV	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25707013]
MT4	CC₅₀	>6.5 μM Compound: EFV	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25907370]
MT4	EC₅₀	0.0054 μM Compound: EFV	Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay	[PMID: 25907370]
MT4	EC₅₀	0.14 μM Compound: EFV	Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay	[PMID: 25907370]
MT4	CC₅₀	37 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT method Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT method	[PMID: 25913116]
MT4	EC₅₀	0.002 μM Compound: EFV	Antiviral activity against HIV1 infected in human MT4 cells assessed as protection against viral-induced cytopathogenecity after 4 days by MTT method Antiviral activity against HIV1 infected in human MT4 cells assessed as protection against viral-induced cytopathogenecity after 4 days by MTT method	[PMID: 25913116]
MT4	CC₅₀	>6336 nM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay	[PMID: 25935383]
MT4	EC₅₀	155 nM Compound: EFV	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection from virus-induced cytopathicity after 4 days by MTT assay Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection from virus-induced cytopathicity after 4 days by MTT assay	[PMID: 25935383]
MT4	EC₅₀	6.3 nM Compound: EFV	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathicity after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathicity after 4 days by MTT assay	[PMID: 25935383]
MT4	CC₅₀	40 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells Cytotoxicity against human MT4 cells	[PMID: 26119992]
MT4	EC₅₀	0.002 μM Compound: Efavirenz	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity by MTT assay	[PMID: 26119992]
MT4	CC₅₀	>6336 nM Compound: 3, EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay	[PMID: 26276435]
MT4	EC₅₀	155 nM Compound: 3, EFV	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method Antiviral activity against HIV1 3B expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method	[PMID: 26276435]
MT4	EC₅₀	6.3 nM Compound: 3, EFV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method	[PMID: 26276435]
MT4	CC₅₀	40 μM Compound: efavirenz	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 26358281]
MT4	EC₅₀	0.002 μM Compound: efavirenz	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 26358281]
MT4	CC₅₀	>6.34 μM Compound: Efavirenz	Cytotoxicity against uninfected human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against uninfected human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 26385446]
MT4	EC₅₀	0.0063 μM Compound: Efavirenz	Antiviral activity against wild type HIV 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 26385446]
MT4	EC₅₀	0.049 μg/mL Compound: Efavirenz	Antiviral activity against HIV 1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV 1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 26385446]
MT4	CC₅₀	38 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 26443549]
MT4	EC₅₀	0.005 μM Compound: EFV	Antiviral activity against HIV-1 infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV-1 infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 26443549]
MT4	CC₅₀	40 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell proliferation after 96 hrs by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell proliferation after 96 hrs by MTT assay	[PMID: 26479028]
MT4	EC₅₀	0.002 μM Compound: EFV	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 26479028]
MT4	EC₅₀	0.005 μM Compound: EFV	Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.0054 μM Compound: EFV	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.0068 μM Compound: EFV	Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.1 μM Compound: EFV	Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.12 μM Compound: EFV	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.21 μM Compound: EFV	Antiviral activity against HIV1 RES056 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.34 μM Compound: EFV	Antiviral activity against HIV1 3B expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.0007 μM Compound: 2; EFV	Antiviral activity against HIV1 BH10 harboring wild type reverse transcriptase infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay Antiviral activity against HIV1 BH10 harboring wild type reverse transcriptase infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay	[PMID: 26804933]
MT4	EC₅₀	0.0018 μM Compound: 2; EFV	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay	[PMID: 26804933]
MT4	EC₅₀	0.037 μM Compound: 2; EFV	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay	[PMID: 26804933]
MT4	EC₅₀	0.058 μM Compound: 2; EFV	Antiviral activity against HIV1 harboring reverse transcriptase Y181C/K103N double mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay Antiviral activity against HIV1 harboring reverse transcriptase Y181C/K103N double mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay	[PMID: 26804933]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay	[PMID: 26994843]
MT4	EC₅₀	0.0054 μM Compound: EFV	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	[PMID: 26994843]
MT4	EC₅₀	0.225 μM Compound: EFV	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	[PMID: 26994843]
MT4	CC₅₀	>6.3 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells after 5 days MTT assay Cytotoxicity against human MT4 cells after 5 days MTT assay	[PMID: 27112451]
MT4	EC₅₀	0.006 μM Compound: Efavirenz	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27112451]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against mock-infected human MT4 cells Cytotoxicity against mock-infected human MT4 cells	[PMID: 27234889]
MT4	EC₅₀	0.0027 μM Compound: EFV	Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	EC₅₀	0.004 μM Compound: EFV	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	EC₅₀	0.19 μM Compound: EFV	Antiviral activity against HIV-1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	CC₅₀	>6.3 μM Compound: EFV	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27267005]
MT4	EC₅₀	0.0068 μM Compound: EFV	Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27267005]
MT4	EC₅₀	0.24 μM Compound: EFV	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27267005]
MT4	CC₅₀	20.6 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by cell titer glo based luciferase reporter gene assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by cell titer glo based luciferase reporter gene assay	[PMID: 27371922]
MT4	EC₅₀	0.001 μM Compound: Efavirenz	Inhibition of wild type HIV-1 3B reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay Inhibition of wild type HIV-1 3B reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay	[PMID: 27371922]
MT4	EC₅₀	0.005 μM Compound: Efavirenz	Inhibition of reverse transcriptase Y181C mutant in HIV-1 3B infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay Inhibition of reverse transcriptase Y181C mutant in HIV-1 3B infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay	[PMID: 27371922]
MT4	EC₅₀	0.101 μM Compound: Efavirenz	Inhibition of HIV-1 3B reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay Inhibition of HIV-1 3B reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay	[PMID: 27371922]
MT4	CC₅₀	≥6.34 μM Compound: EFV	Cytotoxicity against mock-infected human MT4 cells assessed as reduction of cell viability after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction of cell viability after 5 days by MTT assay	[PMID: 27501911]
MT4	CC₅₀	>6340 nM Compound: EFV	Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	115.5 nM Compound: EFV	Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	156.1 nM Compound: EFV	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	348.5 nM Compound: EFV	Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	5 nM Compound: EFV	Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	5.2 nM Compound: EFV	Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	514.8 nM Compound: EFV	Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	8.2 nM Compound: EFV	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	80.1 nM Compound: EFV	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	CC₅₀	>6.3 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 27750153]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 28254696]
MT4	CC₅₀	6.3 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 28314514]
MT4	CC₅₀	>9 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 28314598]
MT4	CC₅₀	>0.00633 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 28481112]
MT4	CC₅₀	>6.33 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 28559060]
MT4	CC₅₀	>15839 nM Compound: EFV	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 28628334]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 28987601]
MT4	CC₅₀	40 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 96 hrs by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 96 hrs by MTT assay	[PMID: 29028528]
MT4	CC₅₀	>6.33 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 29291935]
MT4	CC₅₀	40 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 29339251]
MT4	CC₅₀	>2000 nM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 29353724]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 29534929]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 29559197]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 29635166]
MT4	CC₅₀	>6.336 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 29670703]
MT4	CC₅₀	>3000 nM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 30525601]
MT4	CC₅₀	>3.16 μM Compound: 3; EFV	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 30606670]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 30721060]
MT4	CC₅₀	>2 μM Compound: 1; EFV	Cytotoxicity against human MT4 cells measured after 5 days by MTT assay Cytotoxicity against human MT4 cells measured after 5 days by MTT assay	[PMID: 31091477]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay	[PMID: 31421633]
MT4	CC₅₀	>6.35 μM Compound: 3; EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31434039]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31714780]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31735575]
MT4	CC₅₀	>6.3 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay	[PMID: 31767136]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31935327]
MT4	CC₅₀	>6.38 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 32200201]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 32712537]
MT4	CC₅₀	>15839 nM Compound: EFV	Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay	[PMID: 32883642]
MT4	CC₅₀	>6.34 μM Compound: 3; EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 32977301]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 33279288]
MT4	CC₅₀	>6.3 μM Compound: 3; EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 33340914]
MT4	CC₅₀	>6.3 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 33352387]
MT4	CC₅₀	>6.335 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 33567378]
MT4	CC₅₀	>6.33 μM Compound: EFV	Cytotoxicity against in human MT-4 cells after 5 days by MTT assay Cytotoxicity against in human MT-4 cells after 5 days by MTT assay	[PMID: 33851529]
MT4	CC₅₀	>6.34 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 33979774]
MT4	CC₅₀	>6.35 μM Compound: EFV	Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay	[PMID: 34090079]
MT4	CC₅₀	>6.33 μM Compound: EFV	Cytotoxicity against mock infected human MT4 cells by MTT assay Cytotoxicity against mock infected human MT4 cells by MTT assay	[PMID: 34197708]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 34432448]
MT4	CC₅₀	>6.3 μM Compound: EFV	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 34496571]
MT4	CC₅₀	>6340 nM Compound: EFV	Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 34890994]
MT4	CC₅₀	>6.33 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 35073089]
MT4	CC₅₀	>40196 nM Compound: Efavirenz	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 35175760]
MT4	CC₅₀	>6.33 μM Compound: 3; EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay	[PMID: 35640327]
MT4	CC₅₀	>6.34 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 35649164]
MT4	CC₅₀	6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay	[PMID: 35679690]
MT4	CC₅₀	>6.35 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay	[PMID: 36446205]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 36577216]
MT4	CC₅₀	>6.3 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT spectrophotometric assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT spectrophotometric assay	[PMID: 36640458]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 36996328]
MT4	CC₅₀	>6.35 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 37255025]
MT4	CC₅₀	>6.33 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 37393790]
MT4	CC₅₀	>6.34 μM Compound: 3; EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 37536208]
MT4	CC₅₀	>635 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 37976805]
MT4	CC₅₀	>6.35 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 38996652]
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 39094273]
MT4	CC₅₀	>6.349 μM Compound: EFV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT method Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT method	[PMID: 39167895]
MT4	CC₅₀	35 μM Compound: EFV	Cytotoxicity against Homo sapiens (human) MT4 cells after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells after 96 hr by MTT assay	10.1007/s00044-008-9149-5
MT4	EC₅₀	>0.003 μM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	10.1007/s00044-008-9149-5
MT4	CC₅₀	>6.336 μM Compound: EFV	Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay	10.1007/s00044-009-9220-x
MT4	EC₅₀	0.0044 μM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay	10.1007/s00044-009-9220-x
MT4	IC₅₀	18 nM Compound: efv	Antiviral activity against wild type HIV-1 LAI infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay in presence of 40% human serum Antiviral activity against wild type HIV-1 LAI infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay in presence of 40% human serum	10.1039/C0MD00009D
MT4	IC₅₀	2 nM Compound: efv	Antiviral activity against wild type HIV-1 LAI infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay Antiviral activity against wild type HIV-1 LAI infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	10.1039/C0MD00009D
MT4	IC₅₀	3 nM Compound: efv	Antiviral activity against NNRTI-resistant HIV-1 LAI harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV-1 LAI harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	10.1039/C0MD00009D
MT4	IC₅₀	65 nM Compound: efv	Antiviral activity against NNRTI-resistant HIV-1 LAI harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay Antiviral activity against NNRTI-resistant HIV-1 LAI harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	10.1039/C0MD00009D
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	10.1039/C3MD00028A
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	10.1039/C3MD00028A
MT4	EC₅₀	0.0054 μM Compound: EFV	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	10.1039/C3MD00028A
MT4	CC₅₀	>6.34 μM Compound: EFV	Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
MT4	EC₅₀	0.0089 μM Compound: EFV	Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
MT4	EC₅₀	0.51 μM Compound: EFV	Antiviral activity against HIV-1 RES056 harboring RT K103N+Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay Antiviral activity against HIV-1 RES056 harboring RT K103N+Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
MT4	CC₅₀	0.32 μM Compound: Efavirenz	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	10.1039/C4MD00282B
MT4	EC₅₀	0.98 nM Compound: Efavirenz	Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	10.1039/C4MD00282B
Neuron	EC₅₀	1.5 μM Compound: EFV	Neurotoxicity in mouse primary neurons assessed as loss of MAP-2 intensity incubated for 48 hrs by imaging analysis Neurotoxicity in mouse primary neurons assessed as loss of MAP-2 intensity incubated for 48 hrs by imaging analysis	[PMID: 37130343]
PBMC	EC₅₀	0.0003 μM Compound: EFV	Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	[PMID: 18316521]
PBMC	EC₅₀	0.0004 μM Compound: EFV	Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	[PMID: 18316521]
PBMC	EC₅₀	0.0005 μM Compound: EFV	Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	[PMID: 18316521]
PBMC	EC₅₀	0.0007 μM Compound: EFV	Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	[PMID: 18316521]
PBMC	EC₅₀	0.12 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype G isolate G3 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype G isolate G3 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.15 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR019 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR019 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.16 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype B isolate WEJO infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype B isolate WEJO infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.19 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 93MW959 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 93MW959 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.3 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92RW020 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92RW020 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.34 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG035 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG035 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.39 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype E isolate 93TH073 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype E isolate 93TH073 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.42 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR029 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR029 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.48 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype E isolate 92TH006 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype E isolate 92TH006 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.52 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype G isolate RU132 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype G isolate RU132 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.53 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG001 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG001 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.62 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92UG029 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92UG029 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.7 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype G isolate JV1083 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype G isolate JV1083 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.72 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG024 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG024 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.74 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR020 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR020 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.76 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype B isolate JR-CSF infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype B isolate JR-CSF infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	0.78 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype E isolate CMU08 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype E isolate CMU08 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	1.11 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92UG037 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92UG037 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	1.17 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype B isolate 93BR021 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype B isolate 93BR021 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	1.47 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 93IN101 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 93IN101 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	194 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype O isolate BCF03 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype O isolate BCF03 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	2.08 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 92BR025 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 92BR025 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	57.2 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype O isolate BCF02 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype O isolate BCF02 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	EC₅₀	72.8 nM Compound: EFV	Antiviral activity against Human immunodeficiency virus 1 subtype O misolate BCF01 infected in human PBMC cells by cell based assay Antiviral activity against Human immunodeficiency virus 1 subtype O misolate BCF01 infected in human PBMC cells by cell based assay	[PMID: 19933797]
PBMC	CC₅₀	>100 μM Compound: EFV	Cytotoxicity against HIV1 infected human PBMC cells assessed as reduction in cell viability after 7 days by MTT assay Cytotoxicity against HIV1 infected human PBMC cells assessed as reduction in cell viability after 7 days by MTT assay	[PMID: 27390064]
SUP-T1	CC₅₀	15500 nM Compound: EFV	Cytotoxicity against human SupT1 cells infected with HIV1 3B Cytotoxicity against human SupT1 cells infected with HIV1 3B	[PMID: 19104010]
SUP-T1	EC₅₀	0.5 nM Compound: EFV	Antiviral activity against HIV1 infected in SupT1 cells assessed as accumulation of integrated junction products after 48 hrs by Alu-PCR assay Antiviral activity against HIV1 infected in SupT1 cells assessed as accumulation of integrated junction products after 48 hrs by Alu-PCR assay	[PMID: 19104010]
SUP-T1	EC₅₀	5 nM Compound: EFV	Antiviral activity against HIV1 infected in SupT1 cells assessed as accumulation of late RT products after 12 hrs Antiviral activity against HIV1 infected in SupT1 cells assessed as accumulation of late RT products after 12 hrs	[PMID: 19104010]
SUP-T1	IC₅₀	0.6 nM Compound: Efavirenz	Antiviral activity against HIV RF infected in human SupT1 cells Antiviral activity against HIV RF infected in human SupT1 cells	[PMID: 19748778]
SUP-T1	IC₅₀	1.4 nM Compound: Efavirenz	Antiviral activity against VSV-G pseudotyped HIV1 infected in human SupT1 cells after 48 hrs by luciferase reporter gene assay Antiviral activity against VSV-G pseudotyped HIV1 infected in human SupT1 cells after 48 hrs by luciferase reporter gene assay	[PMID: 27434426]
T-cell	CC₅₀	15 μM Compound: Efavirenz	Cytotoxicity against human CD4-positive T cells Cytotoxicity against human CD4-positive T cells	[PMID: 26487915]
T-cell	EC₅₀	15 nM Compound: Efavirenz	Antiviral activity against HIV-1 X4 expressing wild-type reverse transcriptase infected in human CD4+ T cells for 3 days by FACS analysis Antiviral activity against HIV-1 X4 expressing wild-type reverse transcriptase infected in human CD4+ T cells for 3 days by FACS analysis	[PMID: 26487915]
T-cell	EC₅₀	41 nM Compound: Efavirenz	Antiviral activity against HIV-1 X4 expressing reverse transcriptase Y181C mutant infected in human CD4+ T cells for 3 days by FACS analysis Antiviral activity against HIV-1 X4 expressing reverse transcriptase Y181C mutant infected in human CD4+ T cells for 3 days by FACS analysis	[PMID: 26487915]
T-cell	EC₅₀	836 nM Compound: Efavirenz	Antiviral activity against HIV-1 X4 expressing reverse transcriptase K103N mutant infected in human CD4+ T cells for 3 days by FACS analysis Antiviral activity against HIV-1 X4 expressing reverse transcriptase K103N mutant infected in human CD4+ T cells for 3 days by FACS analysis	[PMID: 26487915]
T-cell	EC₅₀	870 nM Compound: Efavirenz	Antiviral activity against HIV-1 X4 expressing reverse transcriptase K101P mutant infected in human CD4+ T cells for 3 days by FACS analysis Antiviral activity against HIV-1 X4 expressing reverse transcriptase K101P mutant infected in human CD4+ T cells for 3 days by FACS analysis	[PMID: 26487915]
TZM	CC₅₀	>50 μM Compound: Efavirenz	Cytotoxicity against human TZM-bl cells assessed as cell viability after 48 hrs by WST1 assay Cytotoxicity against human TZM-bl cells assessed as cell viability after 48 hrs by WST1 assay	[PMID: 25199582]
TZM	CC₅₀	>6300 nM Compound: 3; EFV	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 1 day by CytoTox-Glo assay Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 1 day by CytoTox-Glo assay	[PMID: 33340914]
TZM	CC₅₀	>5 μM Compound: EFV	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability by MTS assay Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability by MTS assay	[PMID: 37130343]
Vero	CC₅₀	>100 μM Compound: EFV	Cytotoxicity against HIV1 infected African green monkey Vero cells assessed as reduction in cell viability after 7 days by MTT assay Cytotoxicity against HIV1 infected African green monkey Vero cells assessed as reduction in cell viability after 7 days by MTT assay	[PMID: 27390064]

In Vitro

Efavirenz (L-743726) is found to be capable of inhibiting, with 95% inhibitory concentrations of ≤ 1.5μM, a panel of nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs)-resistant mutant viruses, each of which expresses a single RT amino acid substitution. Efavirenz is also tested for its activity against a variety of polymerase enzymes and is found to be inactive (IC₅₀>300μM). Efavirenz effectively inhibits several wild-type T-lymphoid cell line-adapted variants. Identical activity (IC₉₅, 1.5 to 3.0 nM) is seen with wild-type primary isolates of the virus in both primary lymphoid and monocytoid cell cultures. Efavirenz also effectively inhibits HIV-1 variants that expressed RT amino acid substitutions which confer the loss of susceptibility to other NNRTIs. For purposes of comparison^[1]. Efavirenz is a non-nucleoside analog reverse transcriptase inhibitor (NNRTI) with IC₅₀ of 60 nM^[2]. Efavirenz inhibits synthesis using an RNA PPT-primed substrate with an IC₅₀ of 17 nM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

After i.v. administration, Efavirenz (L-743726) is cleared rapidly from rats, but it is cleared considerably more slowly from monkeys. The large volume of distribution (two to four times the amount of body water) in both species indicates extensive tissue binding. The oral bioavailability in rats is 16%. In monkeys, the half-life of Efavirenz after administration of a 1 mg/kg i.v. dose exceeded 2.5 h. Efavirenz is well absorbed orally. Administration to monkeys of oral doses as fine suspensions in 0.5% aqueous methylcellulose yields consistently high levels in plasma. A 2.0 mg/kg dose produces peak levels of 0.5μM at approximately 3.0 h. The absolute bioavailability is estimated to be 42%. A 10 mg/kg dose yields a peak level in plasma of 3.22 μM. A 10 mg/kg oral dose given to a single chimpanzee gave concentrations in plasma of 4.12, 2.95, and 2.69 μM at 2, 8, and 24 h after dosing, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 154598-52-4
Appearance Solid
Masse moléculaire 315.68
Formule C₁₄H₉ClF₃NO₂
Color White to off-white
SMILES

ClC1=CC=C(NC(O[C@]2(C#CC3CC3)C(F)(F)F)=O)C2=C1
Synonyms

DMP 266; EFV; L-743726
Structure Classification
- Others
Initial Source
- Endogenous metabolite
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (17)

All In Vivo Efficacy StudyCell Proliferation/Viability AssayCell Imaging/StainingIHCHistological Imaging/StainingBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Nat Metab

Cholesterol metabolic reprogramming mediates microglia-induced chronic neuroinflammation and hinders neurorestoration following stroke. [Abstract]

2025 Sep 23. PMID: 40987840

Efavirenz purchased from MedChemExpress. Usage Cited in: Nat Metab. 2025 Sep 23. [Abstract]

Efavirenz (EFV) (0.09 mg/kg; i.g.; once daily) reduced foot-fault rates, increased rotarod latency to fall, and enhanced the cognitive performance of MCAO mice.

Efavirenz purchased from MedChemExpress. Usage Cited in: Nat Metab. 2025 Sep 23. [Abstract]

Efavirenz (EFV) (0.09 mg/kg; i.g.; once daily) treatment markedly reduced lipid droplet accumulation in microgliaof MCAO mice.

Efavirenz purchased from MedChemExpress. Usage Cited in: Nat Metab. 2025 Sep 23. [Abstract]

Efavirenz (EFV) (0.09 mg/kg; i.g.; once daily) treatment increased striatal myelin density of MCAO mice.

Efavirenz purchased from MedChemExpress. Usage Cited in: Nat Metab. 2025 Sep 23. [Abstract]

Efavirenz (EFV) (0.09 mg/kg; i.g.; once daily) significantly improved G-ratios in MCAO mice, confirming enhanced myelin repair.

Efavirenz purchased from MedChemExpress. Usage Cited in: Nat Metab. 2025 Sep 23. [Abstract]

Efavirenz (EFV) (0.09 mg/kg; i.g.; once daily) treatment significantly downregulated pro-inflammatory transcripts of microglia in MCAO mice.
Nat Chem Biol

Chemical inhibition of DPP9 sensitizes the CARD8 inflammasome in HIV-1-infected cells. [Abstract]

2023 Apr;19(4):431-439. PMID: 36357533
Cell Rep Med

Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines. [Abstract]

2024 Aug 26:101702. PMID: 39216479
Proc Natl Acad Sci U S A

Human endogenous retrovirus-K (HERV-K) reverse transcriptase (RT) structure and biochemistry reveals remarkable similarities to HIV-1 RT and opportunities for HERV-K-specific inhibition. [Abstract]

2022 Jul 5;119(27):e2200260119. PMID: 35771941
J Med Chem

Selective and Orally Bioavailable Dipeptidyl Peptidase 9 Inhibitors with Potent Pyroptosis Induction Properties. [Abstract]

2025 Oct 29. PMID: 41160575
J Photochem Photobiol A Chem

2025 Nov 15;473:116930.
Int J Antimicrob Agents

Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro. [Abstract]

2019 Dec;54(6):814-819. PMID: 31479744
Mol Divers

A potent and selective PROTAC degrader of CDK9 as effective inhibitor of HIV-1 RNA synthesis. [Abstract]

2025 Nov 12. PMID: 41225073
Viruses

2025 Dec 24;18(1):33.
Nutr Res

Resveratrol attenuates efavirenz-induced hepatic steatosis and hypercholesterolemia in mice by inhibiting pregnane X receptor activation and decreasing inflammation. [Abstract]

2023 Nov:119:119-131. PMID: 37826994
J Med Microbiol

The antiviral drug efavirenz reduces biofilm formation and hemolysis by Staphylococcus aureus. [Abstract]

2021 Oct;70(10). PMID: 34668851
Cell Physiol Biochem

Efavirenz Induced Suicidal Death of Human Erythrocytes. [Abstract]

2015;37(6):2496-507. PMID: 26699137

Efavirenz purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2015;37(6):2496-507. [Abstract]

Arithmetic means±SEM (n=19) of erythrocyte annexin-V-binding (black bars) following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) presence of Efavirenz (1-4 µg/mL).
University of Szeged

2025.
University of Granada

2025.
bioRxiv

Cholesterol-mediated Lysosomal Dysfunction in APOE4 Astrocytes Promotes α-Synuclein Pathology in Human Brain Tissue. [Abstract]

2025 Feb 14:2025.02.09.637107. PMID: 39975381
Orebro University

2024.
University of Oxford

2019 Jul.

Solvant et solubilité

In Vitro:

DMSO : ≥ 38 mg/mL (120.38 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.1678 mL

15.8388 mL

31.6776 mL

5 mM

0.6336 mL

3.1678 mL

6.3355 mL

10 mM

0.3168 mL

1.5839 mL

3.1678 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (6.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (6.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (6.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Animal Administration^[1]

Mice^[1]
Studies are performed in rats, rhesus monkeys, and a single chimpanzee. For analyses of the drug given to rats intravenously (i.v.), a group (n=4 or 5) of fasted male Sprague-Dawley rats (weight, 250 to 450 g) receive a bolus (at a volume of 1mL/kg of body weight) of Efavirenz in DMSO via a cannula implanted in the right jugular vein. For oral studies, rats are dosed by gavage by using a suspension of Efavirenz prepared in 0.5% aqueous methylcellulose. Similarly, four monkeys receive either an i.v. bolus of the compound in DMSO via the saphenous vein at a volume of 0.1 mL/kg or are administered the compound orally in suspension by using a nasogastric tube. Monkeys are fasted for 18 h prior to dosing. One nonanesthetized, nonfasted male chimpanzee (weight, approximately 60 kg) is dosed orally by voluntary ingestion by using an aqueous suspension of the compound. In all studies, heparinized blood is obtained at appropriate times. Plasma is separated immediately by centrifugation and is stored at -20°C until analysis. Plasma samples are extracted with methylene chloride; this is followed by analysis by high-performance liquid chromatography.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (284 KB)
SDS (774 KB)
- English - EN (774 KB)
- Français - FR (774 KB)
- Deutsch - DE (774 KB)
- Norwegian - NO (774 KB)
- Español - ES (774 KB)
- Swedish - SV (774 KB)
- Italian - IT (774 KB)
- Korean - KR (774 KB)
- Portuguese - PT (774 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Young SD, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1995 Dec;39(12):2602-5. [Content Brief]

[2]. Held DM, et al. Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication. J Biol Chem. 2006 Sep 1;281(35):25712-22. [Content Brief]

[3]. Grobler JA, et al. HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J Biol Chem. 2007 Mar 16;282(11):8005-10. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.1678 mL	15.8388 mL	31.6776 mL	79.1941 mL
	5 mM	0.6336 mL	3.1678 mL	6.3355 mL	15.8388 mL
	10 mM	0.3168 mL	1.5839 mL	3.1678 mL	7.9194 mL
	15 mM	0.2112 mL	1.0559 mL	2.1118 mL	5.2796 mL
	20 mM	0.1584 mL	0.7919 mL	1.5839 mL	3.9597 mL
	25 mM	0.1267 mL	0.6336 mL	1.2671 mL	3.1678 mL
	30 mM	0.1056 mL	0.5280 mL	1.0559 mL	2.6398 mL
	40 mM	0.0792 mL	0.3960 mL	0.7919 mL	1.9799 mL
	50 mM	0.0634 mL	0.3168 mL	0.6336 mL	1.5839 mL
	60 mM	0.0528 mL	0.2640 mL	0.5280 mL	1.3199 mL
	80 mM	0.0396 mL	0.1980 mL	0.3960 mL	0.9899 mL
	100 mM	0.0317 mL	0.1584 mL	0.3168 mL	0.7919 mL

Keywords

Efavirenz

17 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Efavirenz

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Antiparasitic Compound library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Natural Product Diversity Scaffold Library

Alkyne Compound Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) Efavirenz

Voir tous les produits spécifiques à Isoform HIV

Voir tous les produits spécifiques à Isoform Endogenous Metabolite

Voir tous les produits spécifiques à Isoform Parasite

Activité biologique

Chemical Information

Publications (17)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Efavirenz Related Classifications

HY-10572 Related Classifications